SCHEMBL6514221

SCHEMBL6514221

COC(=O)c1cc2cc(C=O)ccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 3/20 0.57
▸ ALDH1A1 P00352 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ PDGFRB P09619 2/20 0.48
▸ PDGFRA P16234 2/20 0.48
▸ HDAC3 O15379 3/20 0.45
▸ HDAC4 P56524 3/20 0.45
▸ HDAC1 Q13547 3/20 0.45
▸ HDAC7 Q8WUI4 3/20 0.45
▸ HDAC2 Q92769 3/20 0.45
▸ HDAC10 Q969S8 3/20 0.45
▸ HDAC11 Q96DB2 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8985809 0.88 ALDH1A1 (0.47) XDHALDH1A1KDM4EHPGDRAB9A
SCHEMBL6515596 0.87 XDH (0.56) XDHALDH1A1KDM4EHPGDRAB9A
SCHEMBL5315440 0.84 KDM4E (0.45) XDHALDH1A1KDM4EHPGDRAB9A
SCHEMBL6518705 0.81 SMAD3 (0.62) ALDH1A1KDM4EHPGDLMNAHSD17B10
SCHEMBL31310313 0.80 RAB9A (0.72) XDHALDH1A1KDM4EHPGDRAB9A
SCHEMBL30694751 0.80 XDH (0.61) XDHALDH1A1KDM4EHPGDRAB9A
SCHEMBL214096 0.80 RAB9A (0.72) XDHALDH1A1KDM4EHPGDRAB9A
SCHEMBL217022 0.80 FLT3 (0.67) XDHALDH1A1KDM4EHPGDRAB9A
SCHEMBL31207830 0.80 FLT3 (0.67) XDHALDH1A1KDM4EHPGDRAB9A
SCHEMBL1615647 0.80 CYP2A6 (0.46) ALDH1A1KDM4EHPGDLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026987-A1 CBI analogues of the duocarmycins and CC-1065 THE SCRIPPS RESEARCH INSTITUTE (US) 2005-02-03 — — US disclosed
WO-2004101767-A2 CBI ANALOGUES OF THE DUOCARMYCINS AND CC-1065 THE SCRIPPS RESEARCH INSTITUTE (US) 2004-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026987-A1 CBI analogues of the duocarmycins and CC-1065 CCNI, SP1, DCK XDH 2660/4885ALDH1A1 4597/4885KDM4E 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback